Autor: |
Premuzic, Vedran, Stevanovic, Ranko, Vilibic-Cavlek, Tatjana, Sirovica, Maja, Stalman, Sara, Bogdanic, Maja, Zilic, Denis, Nakic, Dario, Santini Dusevic, Danijela, Vojkovic, Marina, Barbic, Jerko, Durlen, Ivan, Grdan, Zeljka, Pavlovic, Drasko, Kudumija, Boris, Sefer, Sinisa, Griparic, Davor, Rogic, Dunja, Bubas, Marija, Capak, Krunoslav |
Předmět: |
|
Zdroj: |
Antibodies (2073-4468); Jun2023, Vol. 12 Issue 2, p37, 11p |
Abstrakt: |
Background: The effectiveness of the COVID-19 vaccine may differ in hemodialysis patients. The aim of this prospective multicenter study was to determine the degree of serological response to the SARS-CoV-2 vaccine in the population of dialysis patients and its association with later SARS-CoV-2 infections. Methods: A blood sample was taken for the determination of COVID-19 serological status (IgG antibodies) in 706 dialysis patients 16 weeks after vaccination with the second dose (Pfizer-BioNTech). Results: Only 314 (44.5%) hemodialyzed patients had a satisfactory response to the COVID-19 vaccine. Eighty-two patients (11.6%) had a borderline response, while 310 patients (43.9%) had an unsatisfactory (negative) post-vaccinal antibody titer. A longer dialysis vintage had an increased odds ratio (OR) of 1.01 for the occurrence of COVID-19 positivity after vaccination. In the group of subsequently positive patients, 28 patients (13.6%) died from complications of COVID-19. We have found differences in mean survival time between patients with and without appropriate responses to vaccination in favor of patients with a satisfactory serological response. Conclusions: The results showed that the dialysis population will not have the same serological response to the vaccine as the general population. The majority of dialysis patients did not develop a severe clinical picture or die at the time of positivity for COVID-19. [ABSTRACT FROM AUTHOR] |
Databáze: |
Complementary Index |
Externí odkaz: |
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|